Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
Weycker D, Li X, Wygant GD, Lee T, Hamilton M, Luo X, Vo L, Mardekian J, Pan X, Burns L, Atwood M, Hanau A, Cohen AT. Weycker D, et al. Among authors: mardekian j. Thromb Haemost. 2018 Nov;118(11):e1-e2. doi: 10.1055/s-0039-3400530. Epub 2020 Jan 27. Thromb Haemost. 2018. PMID: 31986533 Free PMC article. No abstract available.
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients.
Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH. Li XS, et al. Among authors: mardekian j. Thromb Haemost. 2017 Jun 2;117(6):1072-1082. doi: 10.1160/TH17-01-0068. Epub 2017 Mar 16. Thromb Haemost. 2017. PMID: 28300870 Free PMC article.
Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
Cohen A, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, Mardekian J, Wiederkehr D, Sah J, Luo X. Cohen A, et al. Among authors: mardekian j. Thromb Haemost. 2021 Mar;121(3):383-395. doi: 10.1055/s-0040-1718728. Epub 2020 Nov 10. Thromb Haemost. 2021. PMID: 33171521 Free PMC article.
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach.
Li X, Keshishian A, Hamilton M, Horblyuk R, Gupta K, Luo X, Mardekian J, Friend K, Nadkarni A, Pan X, Lip GYH, Deitelzweig S. Li X, et al. Among authors: mardekian j. PLoS One. 2018 Jan 26;13(1):e0191722. doi: 10.1371/journal.pone.0191722. eCollection 2018. PLoS One. 2018. PMID: 29373602 Free PMC article.
Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States.
Deitelzweig S, Guo JD, Hlavacek P, Lin J, Wygant G, Rosenblatt L, Gupta A, Pan X, Mardekian J, Lingohr-Smith M, Menges B, Marshall A, Nadkarni A. Deitelzweig S, et al. Among authors: mardekian j. Clin Appl Thromb Hemost. 2018 Dec;24(9_suppl):261S-268S. doi: 10.1177/1076029618800806. Epub 2018 Nov 15. Clin Appl Thromb Hemost. 2018. PMID: 30433823 Free PMC article.
160 results